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Glucocorticoid uncoupling of angiotensin Il-dependent phospholipase
C activation in rat vascular smooth muscle cells. Vascular tone is
maintained by both angiotensin II (Ang II) and glucocorticoids, but the
effect of glucocorticoids on Ang II function in vascular smooth muscle
cells (VSMC) is unclear. To determine the direct influence of glucocor-
ticoids on VSMC Ang II receptor function, the effects of dexamethasone
on Ang H receptor binding, Ang Il-induced phospholipase C (PLC)
activation, and Ang Il-dependent cell growth were studied in cultured rat
VSMC. Dexamethasone caused concentration- and time-dependent in-
creases in Ang II binding which were prevented by glucocorticoid receptor
inhibition with RU 38486. Dexamethasone-induced enhancement of Ang
II binding resulted from increased AT1 receptors, as indicated by North-
ern blot analysis and competitive binding assays. Despite causing in-
creased Ang H receptor number, dexamethasone preincubation prevented
Ang LI-induced PLC activation, as indicated by phosphatidylinositol
4,5-bisphosphate degradation and inositol trisphosphate formation. When
PLC activity was directly measured in VSMC soluble and membrane
fractions, Mg II receptor activation caused decreased soluble and in-
creased membrane PLC activity, consistent with the interpretation that
Mg II caused cytosol-to-membrane PLC translocation. The effect of Mg
II on PLC translocation was prevented by dexamethasone preincubation.
Finally, prolonged incubation with dexamethasone and Ang II had
additive effects on VSMC hypertrophy. In conclusion, glucocorticoids
directly altered Ang II function in VSMC by causing increased Ang IL
receptor number, Mg II receptor/PLC uncoupling, and enhanced Mg
IT-dependent hypertrophy.
Glucocorticoids and angiotensin II (Ang II) are both critical in the
regulation of total body sodium, plasma volume, and blood
pressure [1, 2]. Previous studies have demonstrated that glucocor-
ticoids increase plasma renin [3], angiotensinogen mRNA expres-
sion [4], and circulating angiotensinogen levels [5]. While these
findings support the contention that the renin-angiotensin system
may mediate the vascular effects of glucocorticoids, there are few
studies which examine the direct effect of glucocorticoids on Ang
II action in vascular tissue [3, 6].
Ang II function in vascular smooth muscle cells (VSMC) is
initiated by Ang II binding to specific VSMC receptors. Numerous
factors have been identified which affect Ang II binding to VSMC
receptors, including Ang II [7], aldosterone [8], potassium [9], and
glucocorticoids [10].
VSMC Ang II receptors are coupled to phospholipase C (PLC)
by guanine nucleotide-binding proteins [11]. Ang II receptor/PLC
coupling appears to be tight since factors which alter Ang II
receptor number are associated with corresponding changes in
inositol trisphosphate (1P3) formation [9, 12, 13]. The effect of
glucocorticoids on VSMC Ang II receptor/PLC coupling is un-
clear since previous studies have yielded divergent results [14, 15].
Ang II receptor activation also results in VSMC hypertrophy
[16, 17]. While glucocorticoids may affect VSMC growth [14], the
effect of glucocorticoids on Ang II receptor-mediated VSMC
hypertrophy has not been established.
The purpose of our studies was to determine the direct effects
of glucocorticoids on Ang II receptor expression and function. For
these studies, we used cultured VSMC to avoid confounding in
vivo factors which affect Ang II binding, such as systemic hemo-
dynamics, sodium, potassium, and aidosterone.
Methods
VSMC isolation and maintenance
Rat mesenteric arteiy VSMC were harvested by methods
modified from Ives et a! [18] and Gunther et a! [19], and have
been described by our laboratory [12, 13]. Superior mesenteric
arteries from male Sprague-Dawley rats were excised and digested
in minimal essential medium (MEM), 0.25 mg/mi elastase, 0.75
mg/mI soybean trypsin inhibitor, 1.0 mg/mI collagenase, and 2.0
mg/mi bovine albumin at 37°C for two hours. Suspensions were
centrifuged at 200 X g for 10 minutes, and pellets were resus-
pended in growth medium: 10% fetal calf serum, 1% non-essen-
tial amino acids, 100 U/mI penicillin G, and 100 Lg/mi strepto-
mycin in MEM. VSMC were cultured in a 5% C02/95% air
incubator. Growth media was changed every two to three days,
and VSMC were passaged every seven to ten days. VSMC from
passages three through eight were studied.
Ang II binding
Received for publication February 9, 1994
and in revised form April 13, 1994
Accepted for publication April 14, 1994
© 1994 by the International Society of Nephrology
Ang II binding studies were performed on confluent VSMC
monolayers according to the methods of Gunther et al [19] as
previously reported by our laboratory [20]. Binding/assay buffer
contained 50 mrvi Tris (pH 7.4), 100 mivi NaC1, 5 mrvi KCI, 5 mM
MgCI2, 1% bovine serum albumin, and 0.5 mg/mi bacitracin.
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1231-Ang 11(50 fmol) with varying unlabeled Ang II concentra-
tions (0 to 10 nM) was added to each well (300 jii total volume).
In competitive binding studies, losartan and PD 123319 were used
in the range of 0.1 M to 10 .LM. Binding was conducted under
equilibrium conditions (90 mm, 4°C), and terminated by washing
with ice-cold phosphate-buffered saline. VSMC were detached by
adding 1% SDS and T-radioactivity was counted. Non-specific
binding (in the presence of 1 .tM unlabeled Ang II) was less than
15% of total binding. Specific binding was defined as the differ-
ence between total binding and non-specific binding. Ang II
receptor number (Bm) and Ang II binding affinity (Ku) were
determined by Scatchard analysis [21] after binding data was
plotted by least squares fit regression method. Data points were
standardized to cell protein content, which was determined by the
method of Lowiy et al [22]. To further verii' that experimental
conditions did not alter Ang II binding by affecting VSMC growth,
cell counts were determined by hemocytometry, and the observer
was blinded with respect to experimental group.
Northern blot analysis
Total VSMC RNA was extracted with guanidine isothiocyanate
and purified by ultracentrifugation (35,000 X g, 16 hr, 21°C) in
CsCl. RNA (20 big/lane) was fractionated on a denaturing 1.0%
agarose/0.67% formaldehyde gel, transferred to nylon mem-
branes, and baked at 60°C for two hours, To assess AT1 mRNA
levels, cDNA for the rat VSMC AT1 receptor (clone pCal8b,
provided by Dr. K. Bernstein) was labeled by nick-translation with
[a-32P]dCTP to a specific activity of 1.3 x 108 cpm/j.Lg DNA.
Hybridization was conducted in 360 mcs NaCl, 20 mvt Na2HPO4,
2 mri EDTA, 0.1% SDS, and 5 X Denhardt's solution for 16 hours
at 42°C. Filters were washed at high stringency (150 mivi NaC1, 15
m Na citrate, 0.1% SDS) for one hour at 62°C and exposed to
Kodak XAR film for eight hrs at —70°C. Each blot was simulta-
neously hybridized with GAPDH cDNA (indicating generalized
changes in polymerase II activity). Blots were analyzed and
quantitated with a Scanmaker IIXE densitometer (Microtek,
Torrance, California, USA) using appropriate software (Adobe
Photo Shop, Mountainview, California, USA, and Scan Analysis,
Cambridge, UK)
Measurement of inositol trisphosphate
Methods were adapted from Berridge et al [231 and previously
described in detail [24]. Subconfluent VSMC were incubated with
10% fetal calf serum in inositol-deficient MEM containing 2.4
CiJml myo-[2-3H] inositol for 40 hours at 37°C. Wells were then
washed with phosphate-buffered saline at 21°C to remove unin-
corporated tracer. VSMC monolayers were incubated with hor-
mones or assay buffer (30 seconds, 21°C) and reactions were
terminated by addition of 20% trichloroacetic acid. The aqueous
phase was extracted with diethyl ether and pH was adjusted to 7.0
with 50 mrt Tris base. Samples were applied to Dowex AG1-X8
anion exchange resin columns and inositol phosphates were
measured by anion exchange column chromatography. 1P3 values
were expressed as % of baseline (ratio of 1P3 content in agonist-
exposed cells to 1P3 content in cells exposed only to assay buffer).
Measurement of phosphoinositides
These methods have previously been described by our labora-
tory [12]. Following Ang II or assay buffer exposure (30 seconds,
21°C), reactions were terminated by adding ice-cold methanol.
VSMC were transferred to glass test tubes containing chloroform!
concentrated HCI (10:1, vol/vol), and vortexed. Tubes were
centrifuged twice; protein pellets and aqueous phase were dis-
carded. The lipid-soluble layer was dissolved under nitrogen,
resuspended in 75 d chloroform/methanol (1:1, vol/vol) and
spotted on Silica Gel-H chromatography plates which were coated
with 1% potassium oxalate. Phosphatidylinositol (P1), phosphati-
dylinositol 4-monophosphate (PIP), and phosphatidylinositol 4,5-
bisphosphate (PIP2) standards were spotted in separate lanes.
Migration solution contained chloroform!methanol/28% NH3
(6:4:1.5, vol/vol/vol). Silica was scraped from sample lanes and
quantified for [3H]-labeled phosphoinositides by liquid scintilla-
tion. PIP2 values were expressed as % of control (ratio of PIP2
content in agonist-exposed VSMC to PIP2 content in VSMC
exposed only to assay buffer).
Measurement of PLC activüy
VSMC were incubated with Ang II or assay buffer (30 seconds,
21°C) and wells were rinsed with phosphate-buffered saline.
Contents were scraped into homogenization buffer (125 mivi NaCI,
25 mii HEPES (pH 7.4), 0.7 mt MgCl2, 0.5 miss EGTA, 10 mM
glucose, 1 mg/mI bovine serum albumin, 1 mtn dithiothreitol, 0.5
mM phenylmethylsulfonyl fluoride, and 2 jtM leupeptin). Suspen-
sions were sonicated, cell fragments and nuclei were pelleted by
centrifugation at 600 X g for five minutes at 4°C. Supernatants
were centrifuged at 225,000 X g for 60 minutes at 4°C in incu-
bation buffer (100 miss KC1, 25 miss HEPES (pH 7.4), 3 mM NaCI,
5 mM MgCl2, 1 mM dithiothreitol, 0.5 miss phenylmethylsulfonyl
fluoride, 2 LM leupeptin). Soluble and membrane fractions were
removed and each sample was standardized for protein content.
Methods for measuring in vitro PLC activity were derived from
Katan and Parker [25]. [3H]-PI or [3H]-PIP2 (15 j.d, 10 j.Ci/ml)
and unlabeled P1 or PIP2 (150 1.d, 1 mM) were evaporated under
nitrogen, resuspended in 10 miss Tris HCI (pH 7.5), and sonicated
at 4°C. Phospholipid hydrolysis was initiated by adding 20 1.d
phospholipid substrate, 50 td sample (27 to 48 ng protein), and 30
j.d buffer (final concentration: 100 miss NaCI, 2 mM CaC12, 4 m
EGTA, 0.04% bovine serum albumin, 0.6% sodium cholate, 5 mM
2-mercaptoethanol, 20 m Tris maleate, pH 6.0) at 37°C for 30
mm. Reactions were terminated by addition of 0.5 ml chloroform!
methanol/concentrated HCI (10:10:0.06, vol/vol/vol) and 0.15 ml 1
N HCI. The aqueous phase was extracted and quantified for
[3H]-labeled inositol phosphates by liquid scintillation. Phospho-
lipid hydrolysis was expressed in imol/min/mg protein.
Measurement of VSMC growth
Protein synthesis was determined by [3H]leucine incorporation
according to the methods of Fine et al [26]. Subconfluent VSMC
monolayers were plated at a density of 40,000 cells per well and
cultured in growth medium for 48 hours. Wells were washed with
phosphate-buffered saline, and VSMC were rendered quiescent
by incubation with 0.4% serum in MEM for 24 to 48 hours. VSMC
were then incubated in medium containing 1 Ci/ml [3H]leucine
with 10 nM dexamethasone (DEX) and/or 100 n Ang II for 24
hours. Wells were then aspirated and washed with ice-cold
phosphate-buffered saline to remove radiolabel. Proteins were
precipated by addition of 1 ml 10% trichloroacetic acid on ice for
30 minutes. Wells were washed with 95% ethanol and dried on
ice. Contents were solubilized in 1% SDS/1 N NaOH and quan-
tified for 3H in a liquid scintillation counter. DNA synthesis was
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Fig. 1. Effect of DEX concentration on VSMCAngII binding. Subconfiuent
VSMC monolayers were incubated with growth media and indicated
concentrations of DEX for 40 hours at 37°C. Ang LI specific binding was
determined according to the Methods. Results are expressed as % control
(Ang II binding in VSMC without DEX incubation). Data represent
means of seven experiments. * P < 0.05 compared to control group.
determined following 24 hours incubation with [3H]thymidine (1
jsCi/ml) and measurement of [3H]thymidine incorporation ac-
cording to methods described above.
Materials
Materials were obtained from the following sources: Sigma
Chemical (St. Louis, Missouri, USA)—MEM, non-essential amino
acids, tlypsin, Ang II, DEX, AVP, penicillin G, streptomycin, elas-
tase, soybean tlypsin inhibitor; Costar (Cambridge, Massachusetts,
USA)—cell culture flasks and plates; Hazelton Research Products
(Denver, Pennsylvania, USA)—inositol-deficient MEM; Hyclone
Laboratories (Logan, Utah, USA)—fetal calf serum; Sasco Co.
(Omaha, Nebraska, USA)—Sprague-Dawley rats; ICN Pharmaceu-
ticals (Plainview, New York, USA)— bovine serum albumin; Upjohn
Co. (Kalamazoo, Michigan, USA)—bacitracin; Avanti Polar-Lipids
Inc. (Peiham, Alabama, USA)—PI, PIP, PIP2; American Radiola-
beled Chemicals (St. Louis, Missouri, USA)—myo-[2-3HJ-inositol,
['I]-Ang II, [3H]-PI, [3H]-PIP2; Cooper Biomedical (Malvern,
Pennsylvania, USA)—collagenase. RU 38486 was a gift from D.
Philibert, Roussel-Uclaf, Romainville, France. Losartan was a gift
from R.D. Smith, DuPont de Nemours, Wilmington, Delaware,
USA. PD 123319 was a gift from D. Taylor, Parke-Davis Pharma-
ceutical Research, Ann Arbor, Michigan, USA.
Statistics
Results are expressed as mean SE. Comparison between two
groups was made by the unpaired, two-tailed, Student's t-test.
Comparisons between more than two groups were made by one-
way analysis of variance with the Bonferroni test for multiple
comparisons. Comparisons were made by two-way analysis of
variance in Table 2. Statistical significance is defined as P < 0.05.
Results
Initial studies were designed to investigate the effect of DEX on
VSMC Ang II receptor binding. Figure 1 reveals that 40 hours
incubation with DEX resulted in concentration-dependent in-
Preincubation with DEX, hours
Fig. 2. Effect of DEX incubation time on Ang II binding. Subconfluent
VSMC monolayers were incubated with growth media and 10 ni DEX for
indicated times at 37°C. Ang II specific binding was determined according
to the Methods. Results are expressed as % control (Ang II binding in
VSMC without DEX incubation). Data represent means of four to six
experiments. * P < 0.05 compared to control group.
creases in Ang II binding, with a threshold (155.3 9.5% of
baseline, baseline = 1071 103 cpm/well) at 10 nM DEX. The
effect of DEX incubation time on Ang II binding is shown in
Figure 2. DEX incubation (10 nM) with VSMC for three hours did
not increase Ang II binding (baseline = 1355 264 cpm/well).
However, DEX incubation for 15 or 40 hours resulted in signifi-
cant increases in Ang II binding. Preincubation with the AT1
receptor antagonist losartan (0.1 to 10 LM, 30 mm, 21°C) com-
pletely inhibited Ang II specific binding in a concentration-
dependent manner in control and DEX-treated VSMC. Preincu-
bation with the AT2 receptor antagonist PD 123319 (0.1 to 10 M,
30 mm, 21°C) had no effect on Ang II binding (data not shown).
These data indicate that DEX caused exclusive increases in AT1
receptor binding.
To determine if DEX-induced Ang II binding increases were
glucocorticoid receptor-mediated, Ang II binding was determined
following incubation with the glucocorticoid receptor inhibitor
RU 38486 [27]. As seen in Figure 3, incubation with RU 38486 (1
jLM, 40 hr) was associated with small elevations in Ang II binding
(127.0 8.3% of baseline, baseline = 1819 310 cpm/well). The
figure indicates that DEX (10 nrvi, 40 hr incubation) induced Ang
II binding increases (196.4 8.6% of baseline) which were
abolished by RU 38486 co-incubation (132.9 8.0% of baseline).
To evaluate whether DEX-mediated Ang II binding increases
were due to increased Bmax or decreased K0, Scatchard analysis of
Ang II binding data was performed on VSMC incubated with
growth media in the presence or absence of DEX (10 nM, 40 hr).
Table 1 demonstrates that DEX exposure did not affect Ang II
receptor K0. In contrast, DEX-induced increases in Ang II
binding were mediated by increases in Ang II receptor number, as
Ang II receptor Bmax was 69% greater in DEX-treated VSMC
compared to controls. Increases in Ang II binding occurred
independently of changes in VSMC growth, as total cell protein
and cell number were not increased by DEX incubation (control:
202.2 13.2 mg protein/well, 1.1 0.1 X iO cells/well; DEX:
196.5 11.6 mg protein/well, 0.8 0.1 X iO cells/well).
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Fig. 3. Effect of DEX and RU 38486-induced glucocorticoid receptor inhi-
bition on VSMC Ang II binding. Subconfluent VSMC monolayers were
incubated with growth media containing 1 M RU 38486, 10 nM DEX,
both hormones, or no hormones for 40 hours at 37°C. Ang II specific
binding was determined according to the Methods. Results are expressed
as % control (Ang II binding in VSMC without hormone incubation).
Data represent means of seven experiments. * P < 0.01 compared to
DEX-treated group.
Since the predominant mechanism of steroid hormone action is
by binding to DNA and altering transcription [283, we questioned
whether DEX-induced Bmax increases were due to increases in
Ang II receptor mRNA concentration. To test this hypothesis,
steady-state AT1 receptor mRNA levels were measured by North-
ern blot analysis. As shown in Figure 4, DEX-treated (10 nM, 40
hr) VSMC demonstrated increases in AT1 mRNA levels (185.5
2,5% of baseline).
Since VSMC Ang II binding increases are usually associated
with increased PLC signal transduction, we anticipated that
DEX-induced Ang II receptor Bm increases would be associated
with enhanced PIP2 hydrolysis. To determine the effect of DEX
on Ang Il-induced PLC activation, 1P3 formation was measured in
VSMC incubated in growth media containing DEX (10 nM, 40 hr),
and then exposed to Ang 11(100 nM, 30 seconds). As shown in
Figure 5, DEX incubation alone (no Ang II) caused small
decreases in 1P3 (87.8 6.1% of baseline, baseline = 288.3 21.3
cpm per well). Exposure to Ang II caused 1P3 increases (126.3
2.5% of baseline), while DEX preincubation prevented Ang
11-induced 1P3 formation (96.7 3.2% of baseline). Figure 5 also
shows that VSMC exposure to A\TP (100 nrvi, 30 seconds) caused
significant 1P3 increases (141.5 3.5% of baseline). In contrast to
Mg H, DEX preincubation did not affect AVP-induced 1P3
generation (150.6 6.8% of baseline). This data suggest that
DEX effects on PLC signaling were not generalized, but specific
to Ang II receptor/PLC coupling.
To test whether the observed effects of DEX on Aug Il-induced
PLC activation were due to its glucocorticoid properties, Ang
Il-induced 1P3 formation was measured following DEX co-incu-
bation with RU 38486. As seen in Figure 6, DEX preincubation
(10 nM, 40 hr) blocked Aug 11(100 nM)-induced 1P3 formation
(104.5 6.0% of baseline, baseline = 261.1 10.6 cpm per well).
However, co-incubation with RU 38486 (1 M) reversed the
Incubation conditions K0 flM Bmax fmol/mg protein
Control 5.1 0.7 99.4 14.8
DEX 10 nM, 40 hrs 4.1 0.7 168.4 23.Oa
inhibitory effect of DEX on Ang Il-induced 1P3 formation (120.0
4.0% of baseline).
To confirm that DEX-mediated effects on Ang Il-induced 1P3
formation were due to inhibition of phosphoinositide-specific
PLC activation, VSMC were incubated with DEX and PLC
stimulation was assessed by measuring P1 and PIP2 degradation.
As shown in Figure 7, DEX incubation (10 nM, 40 hr) had little
effect on baseline VSMC PIP2 levels (113.0 13.4% of baseline,
baseline = 542.8 54.6 cpm per sample), indicating that DEX did
not alter VSMC incorporation of myo-[2-3H] inositol. VSMC
exposure to Ang 11(100 nM, 30 seconds) caused VSMC PIP2
decreases (78.2 1.5% of baseline). Figure 7 also shows that
DEX preincubation inhibited Ang Il-induced PIP2 breakdown
(113.1 12.9% of baseline), suggesting that DEX impaired Mg
11-induced, phosphoinositide-specific PLC stimulation, Similar
results were observed when P1 degradation was measured (data
not shown).
To determine the mechanism by which DEX impaired Ang
11-induced phosphoinositide hydrolysis, experiments were de-
signed to evaluate direct effects of DEX on PLC activity. Initial
studies revealed that Ang II incubation (100 nrvi, 30 seconds)
caused increased P1 hydrolysis in VSMC membrane fractions and
decreased P1 hydrolysis in soluble VSMC fractions. These effects
of Ang II on PLC activity were completely reversed by DEX (10
nM, 40 hr) preincubation (data not shown). Qualitatively similar
results were observed when PIP2 was used as substrate for PLC.
As shown in Table 2, Mg II (100 nM, 30 seconds) caused
increased PIP2 hydrolysis in membrane VSMC fractions, and
DEX (10 nM, 40 hr) preincubation inhibited the effect of Ang II
on membrane-bound PLC. When soluble PLC was assayed, Aug
II exposure caused decreased enzyme activity. The Ang II effect
on soluble PLC was inhibited by DEX preincubation. AVP also
caused increases in membrane-bound PLC activity and decreases
in soluble PLC activity, but these changes were not prevented by
DEX preincubation.
Since DEX prevented Mg Il-dependent PLC activation, we
questioned whether DEX altered other Ang II receptor functions.
Mg II incubation with cultured VSMC has been shown to cause
cellular hypertrophy [16, 17]. To determine the effect of DEX on
Aug Il-dependent VSMC growth, cultured VSMC were incubated
with DEX and/or Mg II. Table 3 reveals that DEX or Aug II
incubation for 24 hours caused VSMC hypertrophy, as deter-
mined by increases in the ratio of [3H]leucine:[3H]thymidine
incorporation. Co-incubation of RU 38486 with DEX inhibited
VSMC hypertrophy. Co-incubation of Ang II with DEX resulted
in additive VSMC hypertrophy. In DEX-treated VSMC, [3H]
leucine incorporation did not differ significantly compared to
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Table 1. Effect of DEX on VSMC Ang II receptor number (Bmax) and
Aug II binding affinity (K0)
Subconfluent VSMC monolayers were incubated in growth media with
(N = 5) or without (N = 4)10 nM DEX. Bmax and K were determined
by Scatchard analysis as described in the Methods.
P < 0.05 compared to Control
RU38486 DEX RU38486
+ DEX
B
— + — +
— 3.7kb —
•23kbp
1.00 1.83 1.00 1.88
A
DEX
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Relative AT1:
GAPDH mRNA levels
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30 sec — Ang II Ang II AVP AVP
incubation
Fig. 5. Effect of DEX on Ang II- and vasopressin (A VP)-mediated VSMC
1P3 formation. Subconfluent VSMC monolayers were incubated with 10%
fetal calf serum inositol-deficient media containing myo-[2-3H]inositol
with or without 10 flM DEX for 40 hours at 37°C. Confluent monolayers
were exposed to 100 nivi Ang II, 100 nM AVP, or assay buffer for 30
seconds at 21°C. 1P3 was measured according to the Methods. Results are
expressed as % control (1P3 formation in VSMC without hormone
incubation). Data represent means of six to eight experiments. * P < 0.01
compared to Ang II alone.
controls (data not shown). Increases in the [3H]leucine:[3H]thy-
midine ratio were due primarily to decreased [3H]thymidine
incorporation.
Discussion
The results of our studies indicated that cultured rat VSMC
incubation with DEX resulted in glucocorticoid-specific, concen-
tration- and time-dependent increases in Ang II binding. En-
hanced binding was caused by increases in AT1 Bmax which
resulted primarily from receptor synthesis, as evidenced by DEX
enhancement of steady-state AT1 mRNA levels. Despite causing
increased Ang II binding, DEX preincubation prevented Ang
11-induced 1P3 formation, PIP2 degradation, decreases in cytosolic
and increases in membrane-bound PLC activity. These effects
were selective for Ang II, since DEX did not alter AVP-induced
1P3 formation or AVP-induced changes in cytosolic or membrane-
bound PLC activity. Finally, DEX effects were not generalized to
0
40 hrs
preincubation
Fig. 4. Effect of DEX incubation on VSMC AT1
receptor mRNA levels. VSMC were incubated in
media with or without DEX (10 nai, 40 hrs,
37°C). Steady-state AT1 mRNA levels were
measured by Northern blot analysis and
standardized to corresponding GAPDH mRNA
values as described in Methods. Control AT1:
GAPDH mRNA levels were normalized to
1.00. Data represent two experiments (A and
B).
30sec Angll
incubation
Fig. 6. Effect of DEX and RU 38486 on Ang 11-mediated VSMC 1P3
formation. Subconfluent VSMC monolayers were incubated with 10%
fetal calf serum in inositol-deficient media containing myo-[2-3H] inositol
10 nM DEX 1 JLM RU 38486 for 40 hours at 37°C. Confluent
monolayers were exposed to 100 nM Ang II or assay buffer for 30 seconds
at 21°C. 1P3 was measured according to the Methods. Results are
expressed as % control (1P3 in VSMC without hormone incubation). Data
represent means of three experiments. * P < 0.05 compared to DEX
Ang II group.
all aspects of Ang II receptor function since DEX did not impair
Ang II receptor-dependent VSMC hypertrophy.
DEX effects on Ang II receptor function were shown to be
glucocorticoid receptor-specific since RU 38486 blocked DEX-
induced changes in Ang II binding, Ang Il-mediated PLC activa-
tion and VSMC hypertrophy. RU 38486 acts by complexing with
cytosolic glucocorticoid receptors, thereby preventing glucocorti-
coid binding. RU 38486 has no intrinsic agonist activity and has
been shown to prevent in vivo and in vitro glucocorticoid activity
[27].
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Fig. 7. Effect of DEX on Ang lI-mediated VSMC PIP2 degradation. Sub-
confluent VSMC monolayers were incubated with 10% fetal calf serum in
inositol-deficient media containing myo-[2-3H] inositol with or without 10
flM DEX for 40 hours at 37°C. Confluent VSMC monolayers were exposed
to 100 nM Ang II or assay buffer for 30 seconds at 21°C. PIP2 was
measured as described in the Methods. Results are expressed as % control
(PIP2 concentration in VSMC without hormone incubation). Data repre-
sent means of five experiments. * P < 0.05 compared to VSMC exposed
to Ang II alone.
Control Ang II Ang II DEX
Membrane fraction 2.37
2.74
2.21
3.03
3.44
2.65
3.16
2.28
3.06
3.55
2.48
2.64
2.05
2.87
3.23
Mean 2.76 2.94a 2.65
SEM 0.22 0.22 0.20
Soluble fraction 3.21
2.54
3.73
3.04
3.45
2.75
2.35
3.43
2.62
2.82
3.10
2.50
3.55
3.17
3.29
Mean 3.18 2.79a 3.12
SEM 0.20 0.18 0.17
Subconfluent VSMC were incubated with growth media 10 aM DEX
for 40 hours at 37°C. Confluent VSMC monolayers were exposed to 100
nM Ang II or assay buffer for 30 seconds at 21°C. PLC activity was
measured according to the Methods, and is expressed as moles PIP2
hydrolyzed/mm/mg protein.
ap < 0.05 compared to other two groups
Compared to other regulators of VSMC Ang II binding, DEX
appeared to be relatively potent. For example, 10 nM aldosterone
incubation for 40 hours caused 35% increases in Ang II binding
[13], while reduction in growth medium potassium by 45%
resulted in 37% Ang II binding increases [9]. By comparison,
incubation with 10 nM DEX for 40 hours consistently caused
greater than 55% increases in Ang II binding. The effect of DEX
on VSMC Ang II receptor Bmax would be even more striking if
[3Hjleucine:[311]thymidine
incorporation ratio
DEX 1.15 0.06
DEX RU 38486 1.01 0.08
Ang II 1.15 0.04
DEX Ang II 1.29 0.05
Subconfluent, quiescent VSMC were incubated with DEX (10 nM), RU
38486 (1 tM), or Ang 11(100 nM) for 24 hours at 37°C. Protein synthesis
was determined by [3H}leucine incorporation and DNA synthesis by[3H]thymidine incorporation as described in the Methods. Controls (no
hormones) were standardized to 1.00. Data represent means of three to
ten experiments per group.
P < 0.05 compared to other groups
Bma were expressed per cell number since DEX had an inhibitory
effect on mitogenesis.
There are numerous mechanisms by which DEX could increase
Ang II receptor Bmax. However, since (a) DEX caused changes in
Ang II receptor Bmax, but not KD, (b) three hours DEX incuba-
tion had no effect on Ang II binding, and (c) DEX incubation
caused quantitatively similar increases in Ang II binding and
steady-state AT1 receptor mRNA, the results suggest that the
predominant mechanism of increased Ang II receptor Bmax is
DEX-mediated increases in AT1 receptor transcription and/or
decreases in degradation of AT1 mRNA. DEX-induced increases
in Ang II receptor transcription could be explained if glucocorti-
coid receptors function as transcription factors by binding to
glucocorticoid response elements [281 which correspond to the
promoter region for the Ang II receptor.
Although DEX induced increases in Ang II receptor Bmax, the
new Ang II receptors did not appear to be coupled to PLC. In
support of this contention, DEX preincubation impaired: (a) Ang
Il-induced 1P3 formation, (b) Ang IT-induced PIP2 degradation,
and (c) Ang Il-induced changes in PLC activity. One hypothesis
that we tested was that DEX-induced increases in Ang II binding
resulted from increases in AT2 receptor expression, since AT2
receptors are not known to be coupled to PLC. However, we
found that DEX-induced increases in Ang II binding were not
associated with increases in AT2 receptor expression, as demon-
strated by the observation that DEX-induced increases in Ang II
binding were not inhibited by preincubation with the AT2 recep-
tor antagonist PD 123319. Furthermore, DEX-mediated uncou-
pling of Ang II receptors from PLC was specific for Ang II
receptors since AVP-induced IP3 formation was not altered by
DEX preincubation.
Ang TI-mediated phospholipid hydrolysis is biphasic, with early
(PLC-mediated) and sustained (primarily phospholipase D-medi-
ated [29]) second messenger generation. Uncoupling between
Ang II receptors and phospholipases has only been described for
sustained signals. Delafontaine et al [301 and Griendling et al [31]
have shown that decreased extracellular potassium or phenylar-
sine oxide administration inhibited prolonged Ang IT-induced
VSMC diacylglycerol formation. Hunyady et al have shown that
phenylarsine oxide uncoupled sustained Ang 11-dependent 1P3
generation in adrenal glomerulosa cells [32]. In each of these
studies, early signaling events were unaffected by uncoupling
stimuli. Our results demonstrated that DEX increased VSMC
Ang 11 receptors, but concomitantly uncoupled Ang II receptors
from initial PIP2 hydrolysis. This observation was unexpected
140
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80
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Angil Angil
Table 2. Effect of DEX on Ang LI-induced VSMC PLC activity
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since we found in previous studies that Ang II receptor Bmax
increases were associated with enhanced 1P3 formation [9, 12, 13]
rather than Ang II receptor/PLC uncoupling.
In previous reports which examined the effect of glucocorticoids
on Ang Il-mediated VSMC PLC activation, divergent results have
been described. Berk et al exposed rat aortic VSMC to 2 M
hydrocortisone for 48 hours and found no effect on Ang II-
stimulated diacyiglycerol or cytosolic calcium [14]. Sato et al
reported that aortic VSMC incubation with 1 /LM DEX for 48
hours enhanced Ang Il-induced 1P3 formation [15]. Perhaps the
disparity between these studies and ours can be partly explained
by differences in glucocorticoids (DEX vs. hydrocortisone) or
VSMC preparations (mesenteric arteries vs. aorta).
As an initial approach to understanding the mechanism of
DEX-induced Ang II receptor/PLC uncoupling, the effect of DEX
on in vitro PLC activity was measured. We found that Ang II
induced rapid decreases in soluble PLC activity, with reciprocal
increases in membrane-bound PLC activity. Moreover, we ob-
served that DEX preincubation reversed Ang Il-induced effects
on PLC activity. One interpretation of this data is that Ang II
caused cytosol-to-membrane PLC movement, and that DEX
impaired Ang TI-induced PLC translocation. This explanation is
particularly plausible since platelet-derived growth factor and
epidermal growth factor have recently been shown to stimulate
translocation of PLC-Ti from cytosol to membrane compartments
[33]. Although Ang II incubation may have caused translocation
of PLC-Ti, Ang II receptors are most likely linked through
guainine nucleotide-binding proteins to PLC-13 [34]. In prelimi-
nary studies, we were unable to demonstrate effects of DEX or
Ang II on translocation of either PLC-/il or PLC-Ti (data not
shown). Other mechanisms of Ang II receptor/PLC uncoupling,
such as DEX-mediated interference with guanine nucleotide-
binding proteins involved in Ang Il-induced PLC signal transduc-
tion [35, 36] are also plausible.
In contrast to the negative regulatory effects of DEX on Ang II
receptor/PLC coupling, incubation with DEX did not block other
VSMC Ang II receptor functions. Specifically, Ang Il-dependent
VSMC hypertrophy was enhanced in the presence of DEX. These
data indicate that the regulatory effects of DEX were not gener-
alized to all aspects of Ang II receptor function, and suggests that
the effect of DEX on Ang IT-dependent VSMC hypertrophy
occurred by PLC-independent mechanisms.
Glucocorticoids interact with the renin-Ang Il-aldosterone axis
at multiple sites. For example, glucocorticoids stimulate release of
renin [3] and angiotensinogen [5]. Glucocorticoids also affect this
hormone cascade indirectly by influencing total body sodium,
potassium, and systemic hemodynamics. Our data indicate that
glucocorticoids directly affect VSMC Ang II receptor function by
altering Ang II receptor synthesis, Ang II receptor/PLC coupling,
and Ang IT-mediated vascular hypertrophy.
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